Science News: Long-Term Safety and Efficacy of Patisiran for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy: 12-Month Results of an Open-Label Extension Study 6/1/2021
Submitted by Hristelina Ilieva, MD, PhD
Edited by Niranjan Singh, MD
This article summarizes the world wide experience of treating patients with HTTR with Patisiran in terms of safety and efficacy. This is a multicenter, open-label extension (OLE) trial that enrolled patients at 43 hospitals or clinical centers in 19 countries.